Shares of Pharming Group (NASDAQ:PHAR - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $8.09, but opened at $8.84. Pharming Group shares last traded at $8.47, with a volume of 230 shares.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on the company. HC Wainwright restated a "buy" rating and set a $37.00 target price on shares of Pharming Group in a research note on Thursday, March 20th. Oppenheimer lifted their price objective on Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a report on Friday, March 14th.
View Our Latest Research Report on PHAR
Pharming Group Price Performance
The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The company's 50-day moving average price is $8.46 and its two-hundred day moving average price is $8.69. The company has a market cap of $581.67 million, a P/E ratio of -32.88 and a beta of -0.08.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.02). The company had revenue of $92.70 million for the quarter, compared to analyst estimates of $76.67 million. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. As a group, sell-side analysts expect that Pharming Group will post -0.2 earnings per share for the current year.
Institutional Investors Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,997 shares of the company's stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company's stock.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
